D
David M. Roth
Researcher at GlaxoSmithKline
Publications - 297
Citations - 32655
David M. Roth is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Belimumab & Internal medicine. The author has an hindex of 62, co-authored 269 publications receiving 30019 citations. Previous affiliations of David M. Roth include Veterans Health Administration & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
TL;DR: The purpose of this study was to develop an equation from MDRD Study data that could improve the prediction of GFR from serum creatinine concentration, and major clinical decisions in general medicine, geriatrics, and oncology are made by using the Cockcroft-Gault formula and other formulas to predict the level of renal function.
Journal Article
A simplified equation to predict glomerular filtration rate from serum creatinine
Andrew S. Levey,Juan P. Bosch,Julia B. Lewis,Shahriari Ali Reza,Nancy L. Rogers,David M. Roth +5 more
Journal ArticleDOI
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis
Changli Wei,Shafic El Hindi,Jing Li,Alessia Fornoni,Nelson Goes,Junichiro Sageshima,Dony Maiguel,S. Ananth Karumanchi,Hui-Kim Yap,Moin A. Saleem,Qing-Yin Zhang,Boris Nikolic,Abanti Chaudhuri,Pirouz Daftarian,Eduardo Salido,Armando Torres,Moro O. Salifu,Minnie M. Sarwal,Franz Schaefer,Christian Morath,Vedat Schwenger,Martin Zeier,Vineet Gupta,David M. Roth,Maria Pia Rastaldi,George W. Burke,Phillip Ruiz,Jochen Reiser +27 more
TL;DR: It is reported that serum soluble urokinase receptor (suPAR) is elevated in two-thirds of subjects with primary FSGS, but not in people with other glomerular diseases, and that a higher concentration of suPAR before transplantation underlies an increased risk for recurrence of FSGS after transplantation.
Journal ArticleDOI
Sequential therapies for proliferative lupus nephritis
Gabriel Contreras,Victoriano Pardo,Baudouin Leclercq,Oliver Lenz,E. Tozman,Patricia O'Nan,David M. Roth +6 more
TL;DR: For patients with proliferative lupus nephritis, short-term therapy with intravenous cyclophosphamide followed by maintenance therapy with mycophenolate mofetil or azathioprine appears to be more efficacious and safer than long-term Therapy with intravenously cycloph phosphamide.